Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 12/20 | 0.53 |
| ▸ | MTTP | P55157 | 11/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20811270 | 1.00 | APOB (0.53) | APOBMTTPEPHX2SMOCCRL2 | |
| SCHEMBL28897480 | 0.83 | EPHX2 (0.46) | APOBMTTPEPHX2CCRL2RXFP1 | |
| SCHEMBL29500843 | 0.82 | EPHX2 (0.46) | APOBMTTPEPHX2SMOCCRL2 | |
| SCHEMBL20826329 | 0.82 | EPHX2 (0.51) | APOBMTTPEPHX2NR1H2 | |
| SCHEMBL390212 | 0.82 | EPHX2 (0.51) | EPHX2NR1H2 | |
| SCHEMBL20790431 | 0.81 | APOB (0.48) | APOBMTTPSMO | |
| SCHEMBL31324550 | 0.81 | EPHX2 (0.50) | APOBMTTPEPHX2 | |
| SCHEMBL1545000 | 0.81 | EPHX2 (0.50) | EPHX2NR1H2 | |
| SCHEMBL5598167 | 0.81 | EPHX2 (0.50) | EPHX2NR1H2 | |
| SCHEMBL1660617 | 0.81 | EPHX2 (0.50) | APOBMTTPEPHX2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | APOB 3972/4885MTTP 2475/4885EPHX2 4131/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | APOB 3972/4885MTTP 2475/4885EPHX2 4131/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | APOB 3972/4885MTTP 2475/4885EPHX2 4131/4885 |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | APOB 3966/4885MTTP 1474/4885EPHX2 4573/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | APOB 3972/4885MTTP 2475/4885EPHX2 4131/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | APOB 3972/4885MTTP 2475/4885EPHX2 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.